Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.